Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Date:9/18/2012

LEXINGTON, Mass., Sept. 18, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the company was awarded U.S. Patent 8,268,971, entitled "Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity."

The patent covers milk derived antibody compositions that specifically target and modulate an apical intestinal receptor and which are formulated for direct delivery to the gastrointestinal tract of a patient.  The patent also covers treatment of diabetes or obesity by using these antibodies to modulate a sugar receptor.  The types of intestinal receptors disclosed in the patent are very broad, and include sugar transporters, ion channels, sensors, and bile acid transporters.

"This patent highlights the broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "Our oral antibodies can address membrane bound targets as well as soluble targets such as TNF for inflammatory bowel disease and radiation induced damage to the mouth and intestines.  Membrane bound targets such as sugar transporters have been implicated in diabetes and obesity, which are very attractive markets for our oral antibodies."

About Avaxia Biologics:

Avaxia is developing orally administered antibody therapeutics that act locally within the digestive tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are injected or infused rather than administered orally because they are destroyed in the digestive tract.  In contrast, we have developed proprietary antibodies that resist digestion.  Our lead product is an oral antibody against tumor necrosis factor (TNF) for inflammatory bowel disease (IBD).  Existing anti-TNF drugs have proven effective for IBD but have serious immunosuppression side effects because they affect the entire body, not just the gastrointestinal (GI) tract where the inflammation occurs.  The goal of our IBD program is to deliver our anti-TNF antibody locally in the GI tract to minimize side effects from systemic drug exposure.  Avaxia also has programs in GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
3. South and Central America Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
5. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
6. CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
7. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
8. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
10. Global Spinal Devices and Biologics Market 2011-2015
11. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... in the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in ... six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she ...
(Date:5/24/2017)... ... 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified ... is known for his distinguished expertise and experience in the diagnosis and treatment of ... in treating renovascular disease and aortic aneurysm . He is known for his ...
(Date:5/24/2017)... Cortland, OH (PRWEB) , ... May 24, 2017 , ... ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, ... smiles while simultaneously improving their oral health and functionality. , Dr. Bedich ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a ... Truth about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). ... Eastern time, will be presented by Captain Rommie Duckworth, LP, a career fire captain ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... prominent for-profit and nonprofit hospitals and health systems in the nation and help ... their institutions, led professional organizations and been instrumental in developing successful hospital and ...
Breaking Medicine News(10 mins):